Citadel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-61,676
| Closed | -$196K | – | 5994 |
|
|
2025
Q1 | $196K | Sell |
61,676
-17,036
| -22% | -$54.2K | ﹤0.01% | 4889 |
|
|
2024
Q4 | $421K | Sell |
78,712
-18,361
| -19% | -$98.2K | ﹤0.01% | 4177 |
|
|
2024
Q3 | $513K | Buy |
97,073
+44,063
| +83% | +$233K | ﹤0.01% | 3767 |
|
|
2024
Q2 | $96.5K | Buy |
+53,010
| New | +$96.5K | ﹤0.01% | 4969 |
|
|
2024
Q1 | – | Sell |
-7,654
| Closed | -$13.5K | – | 6198 |
|
|
2023
Q4 | $13.5K | Buy |
7,654
+7,471
| +4,083% | +$13.1K | ﹤0.01% | 5475 |
|
|
2023
Q3 | $267 | Buy |
+183
| New | +$267 | ﹤0.01% | 5769 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 5897 |
|
|
2023
Q1 | – | Sell |
-1,015
| Closed | -$863 | – | 6002 |
|
|
2022
Q4 | $863 | Buy |
+1,015
| New | +$863 | ﹤0.01% | 5926 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 5992 |
|
|
2022
Q2 | – | Sell |
-404,545
| Closed | -$663K | – | 6114 |
|
|
2022
Q1 | $663K | Buy |
404,545
+336,465
| +494% | +$551K | ﹤0.01% | 4152 |
|
|
2021
Q4 | $165K | Buy |
+68,080
| New | +$165K | ﹤0.01% | 5605 |
|
|
2021
Q3 | – | Sell |
-29,278
| Closed | -$78K | – | 6456 |
|
|
2021
Q2 | $78K | Sell |
29,278
-34,993
| -54% | -$93.2K | ﹤0.01% | 6059 |
|
|
2021
Q1 | $198K | Buy |
+64,271
| New | +$198K | ﹤0.01% | 5423 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 5124 |
|
|
2020
Q3 | – | Sell |
-15,519
| Closed | -$42K | – | 4743 |
|
|
2020
Q2 | $42K | Sell |
15,519
-29,743
| -66% | -$80.5K | ﹤0.01% | 4410 |
|
|
2020
Q1 | $95K | Buy |
+45,262
| New | +$95K | ﹤0.01% | 4374 |
|
|
2019
Q1 | – | Sell |
-16,904
| Closed | -$62K | – | 4587 |
|
|
2018
Q4 | $62K | Sell |
16,904
-4,360
| -21% | -$16K | ﹤0.01% | 4081 |
|
|
2018
Q3 | $182K | Buy |
+21,264
| New | +$182K | ﹤0.01% | 3779 |
|